Evidence map›Paper›PMID 30108863›Full record

ArticleMedChemComm2017

Synergic modulation of the inflammatory state of macrophages utilizing anti-oxidant and phosphatidylserine-containing polymer-lipid hybrid nanoparticles.

Md Zahangir Hosain, Kazuki Yuzuriha, Khadijah, Masafumi Takeo, Akihiro Kishimura, Yoshihiko Murakami, Takeshi Mori, Yoshiki Katayama

Open access · bronzeAbstract read
In one paragraph

Article in MedChemComm, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Cell-Inspired Biomaterials for Modulating Inflammation.Tissue engineering. Part B, Reviews · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 6 countries.

Md Zahangir HosainGraduate School of Systems Life Sciences , Kyushu University , 744 Motooka, Nishi-ku , Fukuoka 819-0395 , Japan . Email: mori.takeshi.880@m.kyushu-u.ac.jp ; Email: ykatatcm@mail.cstm.kyushu-u.ac.jp ; ; Tel: +81 92 802 2851.
Kazuki YuzurihaGraduate School of Systems Life Sciences , Kyushu University , 744 Motooka, Nishi-ku , Fukuoka 819-0395 , Japan . Email: mori.takeshi.880@m.kyushu-u.ac.jp ; Email: ykatatcm@mail.cstm.kyushu-u.ac.jp ; ; Tel: +81 92 802 2851.
KhadijahDepartment of Applied Chemistry, Faculty of Engineering , Kyushu University , 744 Motooka, Nishi-ku , Fukuoka 819-0395 , Japan.ORCID 0000-0003-4447-6177
Masafumi TakeoGraduate School of Systems Life Sciences , Kyushu University , 744 Motooka, Nishi-ku , Fukuoka 819-0395 , Japan . Email: mori.takeshi.880@m.kyushu-u.ac.jp ; Email: ykatatcm@mail.cstm.kyushu-u.ac.jp ; ; Tel: +81 92 802 2851.
Akihiro KishimuraGraduate School of Systems Life Sciences , Kyushu University , 744 Motooka, Nishi-ku , Fukuoka 819-0395 , Japan . Email: mori.takeshi.880@m.kyushu-u.ac.jp ; Email: ykatatcm@mail.cstm.kyushu-u.ac.jp ; ; Tel: +81 92 802 2851.ORCID 0000-0002-0503-1418
Yoshihiko MurakamiDepartment of Organic and Polymer Materials Chemistry, Faculty of Engineering , Tokyo University of Agriculture and Technology , 2-24-16 Naka-cho, Koganei , Tokyo , 184-8588 , Japan.ORCID 0000-0002-2311-5308
Takeshi MoriGraduate School of Systems Life Sciences , Kyushu University , 744 Motooka, Nishi-ku , Fukuoka 819-0395 , Japan . Email: mori.takeshi.880@m.kyushu-u.ac.jp ; Email: ykatatcm@mail.cstm.kyushu-u.ac.jp ; ; Tel: +81 92 802 2851.ORCID 0000-0002-1821-5427
Yoshiki KatayamaGraduate School of Systems Life Sciences , Kyushu University , 744 Motooka, Nishi-ku , Fukuoka 819-0395 , Japan . Email: mori.takeshi.880@m.kyushu-u.ac.jp ; Email: ykatatcm@mail.cstm.kyushu-u.ac.jp ; ; Tel: +81 92 802 2851.
Kyushu University · JPIngenierie des Materiaux polymeres · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory activation of macrophages is a key factor in chronic inflammatory diseases such as ulcerative colitis. The excessive production of reactive oxygen species (ROS)/reactive nitrogen species (RNS) by macrophages causes oxidative stress during the inflammatory response and exaggerates inflammatory lesions in ulcerative colitis. Inhibition of the inflammatory activation of macrophages is a promising treatment for chronic inflammatory diseases. Here, we prepared self-filling polymer-lipid hybrid nanoparticles (PST-PLNPs) consisting of poly dl-lactic acid as a hydrophobic biodegradable polymer core encapsulating α-tocopherol (T) and phosphatidylserine (PS) both on the surface and interior of the particle. We confirmed the anti-inflammatory response of these hybrid nanoparticles in activated murine macrophages. PS has anti-inflammatory effects on macrophages by modulating the macrophage phenotype, while α-tocopherol is an antioxidant that neutralizes ROS. We found that PS-containing (PS-PLNPs) and PS plus α-tocopherol-containing (PST-PLNPs) polymer-lipid hybrid nanoparticles significantly increased the viability of lipopolysaccharide (LPS)-treated macrophages compared with phosphatidylcholine-containing PLNPs. PST-PLNPs had a better effect than PS-PLNPs, which was attributed to the synergy between PS and α-tocopherol. This synergic action of PST-PLNPs reduced NO and pro-inflammatory cytokine (IL-6) production and increased anti-inflammatory cytokine (TGF-β1) production when incubated with activated macrophages. Thus, these self-filling biodegradable polymer-lipid hybrid nanoparticles (PST-PLNPs) containing anti-oxidant and anti-inflammatory molecules might be potential alternative drug carriers to liposomes and polymeric nanoparticles for the treatment of chronic inflammatory diseases such as ulcerative colitis.

Identifiers

PMID30108863
PMCPMC6071953
OpenAlexW2620754844

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.